Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo

Yan,Yulan; Jia,Lijuan; Zhang,Jin; Liu,Yang; Bu,Xuefeng

doi:10.3892/ol.2014.2562

Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo

Authors:
- Yulan Yan
- Lijuan Jia
- Jin Zhang
- Yang Liu
- Xuefeng Bu
View Affiliations

Affiliations: Department of Respiratory Medicine, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212002, P.R. China, Department of General Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu 212002, P.R. China
Published online on: September 25, 2014 https://doi.org/10.3892/ol.2014.2562
Pages: 2569-2576

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Newcastle disease virus (NDV) has been reported to selectively duplicate in and then destroy tumor cells, whilst sparing normal cells. However, the effect of NDV on lung cancer has yet to be elucidated. In the present study, recombinant NDV (rl‑RVG) was applied to lung adenocarcinoma A549 cell tumor‑bearing mice to explore its effect on the proliferation of the cells and the immune response of the mice. Following rl‑RVG transfection, RVG and NDV gene expression, decreased tumor growth, subcutaneous tumor necrosis, tumor apoptosis and an increased number of cluster of differentiation (CD)3‑/CD49+ natural killer cells were more evident in the rl‑RVG group. The present study demonstrated that rl‑RVG transfection effectively restrained lung adenocarcinoma A549 cell growth in vivo, which may have been accomplish by inducing tumor cell apoptosis and regulating the cell immune response.

View Figures

View References

1	Foucault C, Mordant P, Grand B, et al: Unexpected extensions of non-small-cell lung cancer diagnosed during surgery: revisiting exploratory thoracotomies and incomplete resections. Interact Cardiovasc Thorac Surg. 16:667–672. 2013.
2	Wheelock EF and Dingle JH: Observations on the repeated administration of viruses to a patient with acute leukamia. A preliminary report. N Engl J Med. 271:645–651. 1964.
3	Cassel WA and Garrett RE: Newcastle disease virus as an antineoplastic agent. Cancer. 18:863–868. 1965.
4	Reichard KW, Lorence RM and Cascino CJ: Selective replication of Newcastle disease virus (NDV) in cancer cells is associated with virus-induced cell fusion. Proc Am Assoc Cancer Res. 33:5211992.
5	Bukreyev A, Huang Z, Yang L, et al: Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol. 79:13275–13284. 2005.
6	DiNapoli JM, Kotelkin A, Yang L, et al: Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci USA. 104:9788–9793. 2007.
7	DiNapoli JM, Nayak B, Yang L, et al: Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol. 84:1489–1503. 2010.
8	Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A, et al: Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol. 80:1130–1139. 2006.
9	Donahue JM, Mullen JT and Tanabe KK: Viral oncolysis. Surg Oncol Clin N Am. 11:661–680. 2002.
10	Reichard KW, Lorence RM, Cascino CJ, et al: Newcastle disease virus selectively kills human tumor cells. J Surg Res. 52:448–453. 1992.
11	Elankumaran S, Rockemann D and Samal SK: Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol. 80:7522–7534. 2006.
12	Hrabák A, Csuka I, Bajor T and Csatáry LK: The cytotoxic anti-tumor effect of MTH-68/H, a live attenuated Newcastle disease virus is mediated by the induction of nitric oxide synthesis in rat peritoneal macrophages in vitro. Cancer Lett. 231:279–289. 2006.
13	Bian H, Fournier P, Peeters B and Schirrmacher V: Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein. Int J Oncol. 27:377–384. 2005.
14	Lorence RM, Rood PA and Kelley KW: Newcastle disease virus as an antineoplastic agent: induction of tumornecrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst. 80:1305–1312. 1988.
15	Lorence RM, Reichard KW, Katubig BB, et al: Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst. 86:1228–1233. 1994.
16	Cassel WA and Murray DR: Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. Nat Immun Cell Growth Regul. 7:351–352. 1988.
17	Wallack MK, Sivanandham M, Balch CM, et al: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 187:69–79. 1998.
18	Ashraf S, Singh PK, Yadav DK, et al: High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice. J Biotechnol. 119:1–14. 2005.
19	Barth R, Diderrich G and Weinmann E: NIH test, a problematic method for testing potency of inactivated rabies vaccine. Vaccine. 6:369–377. 1988.
20	Ge J, Wang X, Tao L, et al: Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J Virol. 85:8241–8252. 2011.
21	Zamarin D and Palese P: Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 7:3347–3367. 2012.
22	Bazzoni F and Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med. 334:1717–1725. 1996.
23	Zou H, Li Y, Liu X and Wang X: An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 274:11549–11556. 1999.
24	Ravindra PV, Tiwari AK, Sharma B and Chauhan RS: Newcastle disease virus as an oncolytic agent. Indian J Med Res. 130:507–513. 2009.
25	Nelson NJ: Scientific interest in Newcastle disease virus is reviving. J Nat Cancer Inst. 91:1708–1710. 1999.
26	Schirrmacher V, Haas C, Bonifer R, et al: Human tumor cell modification by virus infection: an efficient and safe way to pro duce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 6:63–73. 1999.
27	Fiola C, Peeters B, Fournier P and Unsal A: Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer. 119:328–338. 2006.
28	Avki S, Turutoglu H, Simsek A and Unsal A: Clinical and immunological effects of Newcastle disease virus vaccine on bovine papillomatosis. Vet Immunol Immunopathol. 98:9–16. 2004.
29	Zeng J, Fournier P and Schirrmacher V: Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology. 297:19–30. 2002.